BACKGROUND: Genome scans in African-Americans with end-stage renal disease (ESRD) identified linkage on chromosome 13q33 in the region containing the ephrin-B2 ligand (EFNB2) genes. Interactions between the ephrin-B2 receptor and ephrin-B2 ligand play essential roles in renal angiogenesis, blood vessel maturation, and kidney disease. METHODS: The EFNB2 gene was evaluated as a positional candidate for non-diabetic and diabetic ESRD susceptibility in 1,071 unrelated African-American subjects; 316 with non-diabetic etiologies of ESRD, 394 with type 2 diabetes-associated ESRD and 361 healthy controls. Single nucleotide polymorphism (SNP) genotyping was performed on the Sequenom Mass Array System. Statistical analyses were computed using Dandelion version 1.26, Snpaddmix version 1.4 and Haploview version 3.32. RESULTS: Twenty-eight HapMap tag SNPs were genotyped spanning the 39 kilobases (kb) of the EFNB2 coding region, with average spacing of 1.43 kb. Analysis of 710 ESRD patient samples and 361 controls provided no evidence of single SNP associations in either diabetic or non-diabetic ESRD; although nominal evidence of association with all-cause ESRD was observed with a two SNP (p = 0.022) and three SNP (p = 0.023) haplotype, both containing SNPs rs7490924 and rs2391335 in intron 1. CONCLUSIONS: Although an attractive positional candidate gene, polymorphisms in the EFNB2 gene do not appear to contribute in a substantial way to non-diabetic, diabetic or all-cause ESRD susceptibility in African-Americans. Additional genes within the chromosome 13q33 linkage interval are likely contributors to African-American non-diabetic ESRD. Copyright 2008 S. Karger AG, Basel.
BACKGROUND: Genome scans in African-Americans with end-stage renal disease (ESRD) identified linkage on chromosome 13q33 in the region containing the ephrin-B2 ligand (EFNB2) genes. Interactions between the ephrin-B2 receptor and ephrin-B2 ligand play essential roles in renal angiogenesis, blood vessel maturation, and kidney disease. METHODS: The EFNB2 gene was evaluated as a positional candidate for non-diabetic and diabetic ESRD susceptibility in 1,071 unrelated African-American subjects; 316 with non-diabetic etiologies of ESRD, 394 with type 2 diabetes-associated ESRD and 361 healthy controls. Single nucleotide polymorphism (SNP) genotyping was performed on the Sequenom Mass Array System. Statistical analyses were computed using Dandelion version 1.26, Snpaddmix version 1.4 and Haploview version 3.32. RESULTS: Twenty-eight HapMap tag SNPs were genotyped spanning the 39 kilobases (kb) of the EFNB2 coding region, with average spacing of 1.43 kb. Analysis of 710 ESRDpatient samples and 361 controls provided no evidence of single SNP associations in either diabetic or non-diabetic ESRD; although nominal evidence of association with all-cause ESRD was observed with a two SNP (p = 0.022) and three SNP (p = 0.023) haplotype, both containing SNPs rs7490924 and rs2391335 in intron 1. CONCLUSIONS: Although an attractive positional candidate gene, polymorphisms in the EFNB2 gene do not appear to contribute in a substantial way to non-diabetic, diabetic or all-cause ESRD susceptibility in African-Americans. Additional genes within the chromosome 13q33 linkage interval are likely contributors to African-American non-diabetic ESRD. Copyright 2008 S. Karger AG, Basel.
Authors: Nicholas W Gale; Gavin Thurston; Sean F Hackett; Roumiana Renard; Quan Wang; Joyce McClain; Cliff Martin; Charles Witte; Marlys H Witte; David Jackson; Chitra Suri; Peter A Campochiaro; Stanley J Wiegand; George D Yancopoulos Journal: Dev Cell Date: 2002-09 Impact factor: 12.270
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: Barry I Freedman; Nataliya V Volkova; Scott G Satko; Jenna Krisher; Claudine Jurkovitz; J Michael Soucie; William M McClellan Journal: Am J Nephrol Date: 2005-09-21 Impact factor: 3.754
Authors: Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor Journal: J Am Soc Nephrol Date: 2008-01-30 Impact factor: 10.121
Authors: T Hashimoto; T Karasawa; A Saito; N Miyauchi; G D Han; K Hayasaka; F Shimizu; H Kawachi Journal: Kidney Int Date: 2007-08-01 Impact factor: 10.612
Authors: Keith L Keene; Josyf C Mychaleckyj; Shelly G Smith; Tennille S Leak; Peter S Perlegas; Carl D Langefeld; Barry I Freedman; Stephen S Rich; Donald W Bowden; Michèle M Sale Journal: Diabetes Date: 2008-01-09 Impact factor: 9.461
Authors: Meredith A Bostrom; Lingyi Lu; Jeff Chou; Pamela J Hicks; Jianzhao Xu; Carl D Langefeld; Donald W Bowden; Barry I Freedman Journal: Hum Genet Date: 2010-06-08 Impact factor: 4.132
Authors: Marino A Bruce; Bettina M Beech; Mario Sims; Tony N Brown; Sharon B Wyatt; Herman A Taylor; David R Williams; Errol Crook Journal: J Investig Med Date: 2009-04 Impact factor: 2.895
Authors: Meijian Guan; Jacob M Keaton; Latchezar Dimitrov; Pamela J Hicks; Jianzhao Xu; Nicholette D Palmer; Lijun Ma; Swapan K Das; Yii-Der I Chen; Josef Coresh; Myriam Fornage; Nora Franceschini; Holly Kramer; Carl D Langefeld; Josyf C Mychaleckyj; Rulan S Parekh; Wendy S Post; Laura J Rasmussen-Torvik; Stephen S Rich; Jerome I Rotter; John R Sedor; Denyse Thornley-Brown; Adrienne Tin; James G Wilson; Barry I Freedman; Donald W Bowden; Maggie C Y Ng Journal: Hum Genomics Date: 2019-05-15 Impact factor: 6.481